#1924
Multimodal Treatment of a Metastatic Pancreatic NeuroEndocrine Tumor in Von Hippel Lindau Disease
Introduction:
Von Hippel-Lindau disease (VHL) is an inherited neoplastic syndrome: pancreatic lesions in 35-77% of cases, usually serous cystic adenoma (SCA), but 5-17% are non-functioning (NF) NeuroEndocrine tumors (NETs).
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
Authors:
Milanetto A,
Liço V,
Alaggio R,
Pedrazzoli S,
Pasquali C,
Keywords:
Von Hippel-Lindau disease,
NeuroEndocrine Tumor,
Sunitinib,
#806
Long-Term Prognosis of Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Disease
Introduction:
Management of pancreatic neuroendocrine tumours (PNET) associated with von Hippel-Lindau (VHL) disease is challenging because of their malignant potential and poorly predictable prognosis.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
de Mestier L
Authors:
De Mestier L,
Gaujoux S,
Cros J,
Hentic O,
Vullierme M,
Keywords:
pancreas,
neuroendocrine tumors,
von Hippel-Lindau disease,
natural history,
prognosis,
#40
Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients
Introduction:
Neuroendocrine tumors (NETs) are rare neoplasms, heterogeneous, and with variable biological behavior. NETs can be sporadic or they can arise in complex endocrine hereditary syndromes such as Multiple Endocrine Neoplasias (MEN), Familial Paragangliomatosis (FPGL), Neurofibromatosis type 1 (NF1), von Hippel-Lindau Disease (VHL), Tuberous Sclerosis (TSC) and Carney Complex (CC). By performing genetic screening, patients with hereditary NETs can be identified before the development of tumors.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Authors:
Faggiano A,
Ramundo V,
Milone F,
Severino R,
Lombardi G,
Keywords:
neuroendocrine tumor,
genetic analysis,
MEN1,
MEN2,
paragangliomatosis,
genotype-phenotype correlation.,